Rhythm Pharmaceuticals Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-25 12:19:54 ET
More on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps - Slideshow
- Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster
- Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
- Rhythm Pharma sees Q4 net product revenues from global sales of IMCIVREE to be about $57M
- Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome
Read the full article on Seeking Alpha
For further details see:
Rhythm Pharmaceuticals Q4 2025 Earnings Preview
Rhythm Pharmaceuticals Inc.
NASDAQ: RYTM
RYTM Trading
2.09% G/L:
$93.51 Last:
101,028 Volume:
$92.46 Open:
RYTM Latest News
March 01, 2026 12:30:00 pm
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
February 26, 2026 07:00:00 am
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
RYTM Stock Data
$6,891,165,143
62,665,157
0.73%
95
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
